AstraZeneca (AZN) and Ionis (IONS) Sign Deal to Develop and Commercialise Eplontersen

Go back to AstraZeneca (AZN) and Ionis (IONS) Sign Deal to Develop and Commercialise Eplontersen

Additional Analyses of AstraZeneca's (AZN) ENHERTU Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast Cancer

December 9, 2021 9:46 AM EST

New results from the DESTINY-Breast03 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated higher progression-free survival (PFS) and objective response rate (ORR) in prespecified patient subgroups compared to trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. ENHERTU is a HER2 directed... More

AstraZeneca (AZN) Evusheld Authorized for Emergency Use in the US or Pre-Exposure Prophylaxis (Prevention) of COVID-19

December 8, 2021 4:05 PM EST

AstraZeneca's (NASDAQ: AZN) Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.

The Food and Drug Administration (FDA) granted the EUA for Evusheld for pre-exposure prophylaxis of COVID-19 in adults and adolescents (aged 12 and older who weigh 40kg or more) with moderate to severe immune compromise due to a medical condition or immunosuppressive medications and who may not mount an adequate immune response to COVID-19 vaccination,... More

AstraZeneca (AZN) Said to Study Listing of New Vaccines Division - Bloomberg

December 3, 2021 12:44 PM EST

AstraZeneca (NASDAQ: AZN) Said to Study Listing of New Vaccines Division - Bloomberg

Said to Discuss Range of Options for Unit
... More